A clinical assessment of mycophenolate drug monitoring after liver transplantation

Shin Hwang, Sung Gyu Lee, Chul Soo Ahn, Ki Hun Kim, Deok Bog Moon, Tae Yong Ha, Gi Won Song, Dong Hwan Jung, Nam Kyu Choi, Kwan Woo Kim, Young-Dong Yu, Gil Chun Park, Pyoung Jae Park, Young Il Choi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Recent findings have suggested the clinical utility of therapeutic drug monitoring (TDM) in patients treated with mycophenolate mofetil (MMF). Aim: To assess whether routine mycophenolic acid (MPA) TDM is beneficial and how to utilize it. Methods: A series of short-term prospective studies on TDM for MPA and/or tacrolimus was performed at a large-volume center. Results: The 673 adult liver transplants were divided into four groups based on immunosuppressive regimens as tacrolimus monotherapy (n = 369), tacrolimus-MMF therapy (n = 270), MMF-minimal tacrolimus therapy (n = 17), and MMF monotherapy (n = 17). There was a significant difference of tacrolimus concentration between the groups receiving tacrolimus monotherapy and tacrolimus-MMF therapy during the first two yr (at two yr: 8.4 ± 2.7 vs. 6.3 ± 2.6 ng/mL; p ≤ 0.002). MMF-minimal tacrolimus therapy and MMF monotherapy were applied after first three months and MPA levels ranged from 1.8 to 5.3 μg/mL. Correlation between MMF dosage and MPA concentration showed wide interindividual variations (n = 304, r2 = 0.271, p < 0.001), in which r2 was fluctuating from 0.056 to 0.213 according to the post-transplant period over five yr; wide intraindividual variation was also observed during the first two months (n = 12, r2 < 0.2, p > 0.195). About 10% of patients were classified as poor MMF absorber and excluded from MMF usage. Mean MPA level leading to successful MMF monotherapy or MMF-minimal tacrolimus therapy was ≥1.0 μg/mL in 87% and >2.0 μg/mL in 56.5%. Conclusion: MPA TDM-based MMF dosage adjustment enabled us to administer MMF more confidently than categorical dosing. MPA TDM appears to be a useful tool to cope with the wide pharmacokinetic variability of MMF after liver transplantation.

Original languageEnglish
JournalClinical Transplantation
Volume24
Issue number2
DOIs
Publication statusPublished - 2010 Mar 1
Externally publishedYes

Fingerprint

Mycophenolic Acid
Drug Monitoring
Liver Transplantation
Tacrolimus

Keywords

  • Immunosuppression
  • Liver transplantation
  • Mycophenolate mofetil
  • Mycophenolic acid
  • Therapeutic drug monitoring

ASJC Scopus subject areas

  • Transplantation

Cite this

Hwang, S., Lee, S. G., Ahn, C. S., Kim, K. H., Moon, D. B., Ha, T. Y., ... Choi, Y. I. (2010). A clinical assessment of mycophenolate drug monitoring after liver transplantation. Clinical Transplantation, 24(2). https://doi.org/10.1111/j.1399-0012.2009.01166.x

A clinical assessment of mycophenolate drug monitoring after liver transplantation. / Hwang, Shin; Lee, Sung Gyu; Ahn, Chul Soo; Kim, Ki Hun; Moon, Deok Bog; Ha, Tae Yong; Song, Gi Won; Jung, Dong Hwan; Choi, Nam Kyu; Kim, Kwan Woo; Yu, Young-Dong; Park, Gil Chun; Park, Pyoung Jae; Choi, Young Il.

In: Clinical Transplantation, Vol. 24, No. 2, 01.03.2010.

Research output: Contribution to journalArticle

Hwang, S, Lee, SG, Ahn, CS, Kim, KH, Moon, DB, Ha, TY, Song, GW, Jung, DH, Choi, NK, Kim, KW, Yu, Y-D, Park, GC, Park, PJ & Choi, YI 2010, 'A clinical assessment of mycophenolate drug monitoring after liver transplantation', Clinical Transplantation, vol. 24, no. 2. https://doi.org/10.1111/j.1399-0012.2009.01166.x
Hwang, Shin ; Lee, Sung Gyu ; Ahn, Chul Soo ; Kim, Ki Hun ; Moon, Deok Bog ; Ha, Tae Yong ; Song, Gi Won ; Jung, Dong Hwan ; Choi, Nam Kyu ; Kim, Kwan Woo ; Yu, Young-Dong ; Park, Gil Chun ; Park, Pyoung Jae ; Choi, Young Il. / A clinical assessment of mycophenolate drug monitoring after liver transplantation. In: Clinical Transplantation. 2010 ; Vol. 24, No. 2.
@article{68839ddbb20c4330b7750534e293dc15,
title = "A clinical assessment of mycophenolate drug monitoring after liver transplantation",
abstract = "Background: Recent findings have suggested the clinical utility of therapeutic drug monitoring (TDM) in patients treated with mycophenolate mofetil (MMF). Aim: To assess whether routine mycophenolic acid (MPA) TDM is beneficial and how to utilize it. Methods: A series of short-term prospective studies on TDM for MPA and/or tacrolimus was performed at a large-volume center. Results: The 673 adult liver transplants were divided into four groups based on immunosuppressive regimens as tacrolimus monotherapy (n = 369), tacrolimus-MMF therapy (n = 270), MMF-minimal tacrolimus therapy (n = 17), and MMF monotherapy (n = 17). There was a significant difference of tacrolimus concentration between the groups receiving tacrolimus monotherapy and tacrolimus-MMF therapy during the first two yr (at two yr: 8.4 ± 2.7 vs. 6.3 ± 2.6 ng/mL; p ≤ 0.002). MMF-minimal tacrolimus therapy and MMF monotherapy were applied after first three months and MPA levels ranged from 1.8 to 5.3 μg/mL. Correlation between MMF dosage and MPA concentration showed wide interindividual variations (n = 304, r2 = 0.271, p < 0.001), in which r2 was fluctuating from 0.056 to 0.213 according to the post-transplant period over five yr; wide intraindividual variation was also observed during the first two months (n = 12, r2 < 0.2, p > 0.195). About 10{\%} of patients were classified as poor MMF absorber and excluded from MMF usage. Mean MPA level leading to successful MMF monotherapy or MMF-minimal tacrolimus therapy was ≥1.0 μg/mL in 87{\%} and >2.0 μg/mL in 56.5{\%}. Conclusion: MPA TDM-based MMF dosage adjustment enabled us to administer MMF more confidently than categorical dosing. MPA TDM appears to be a useful tool to cope with the wide pharmacokinetic variability of MMF after liver transplantation.",
keywords = "Immunosuppression, Liver transplantation, Mycophenolate mofetil, Mycophenolic acid, Therapeutic drug monitoring",
author = "Shin Hwang and Lee, {Sung Gyu} and Ahn, {Chul Soo} and Kim, {Ki Hun} and Moon, {Deok Bog} and Ha, {Tae Yong} and Song, {Gi Won} and Jung, {Dong Hwan} and Choi, {Nam Kyu} and Kim, {Kwan Woo} and Young-Dong Yu and Park, {Gil Chun} and Park, {Pyoung Jae} and Choi, {Young Il}",
year = "2010",
month = "3",
day = "1",
doi = "10.1111/j.1399-0012.2009.01166.x",
language = "English",
volume = "24",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - A clinical assessment of mycophenolate drug monitoring after liver transplantation

AU - Hwang, Shin

AU - Lee, Sung Gyu

AU - Ahn, Chul Soo

AU - Kim, Ki Hun

AU - Moon, Deok Bog

AU - Ha, Tae Yong

AU - Song, Gi Won

AU - Jung, Dong Hwan

AU - Choi, Nam Kyu

AU - Kim, Kwan Woo

AU - Yu, Young-Dong

AU - Park, Gil Chun

AU - Park, Pyoung Jae

AU - Choi, Young Il

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Background: Recent findings have suggested the clinical utility of therapeutic drug monitoring (TDM) in patients treated with mycophenolate mofetil (MMF). Aim: To assess whether routine mycophenolic acid (MPA) TDM is beneficial and how to utilize it. Methods: A series of short-term prospective studies on TDM for MPA and/or tacrolimus was performed at a large-volume center. Results: The 673 adult liver transplants were divided into four groups based on immunosuppressive regimens as tacrolimus monotherapy (n = 369), tacrolimus-MMF therapy (n = 270), MMF-minimal tacrolimus therapy (n = 17), and MMF monotherapy (n = 17). There was a significant difference of tacrolimus concentration between the groups receiving tacrolimus monotherapy and tacrolimus-MMF therapy during the first two yr (at two yr: 8.4 ± 2.7 vs. 6.3 ± 2.6 ng/mL; p ≤ 0.002). MMF-minimal tacrolimus therapy and MMF monotherapy were applied after first three months and MPA levels ranged from 1.8 to 5.3 μg/mL. Correlation between MMF dosage and MPA concentration showed wide interindividual variations (n = 304, r2 = 0.271, p < 0.001), in which r2 was fluctuating from 0.056 to 0.213 according to the post-transplant period over five yr; wide intraindividual variation was also observed during the first two months (n = 12, r2 < 0.2, p > 0.195). About 10% of patients were classified as poor MMF absorber and excluded from MMF usage. Mean MPA level leading to successful MMF monotherapy or MMF-minimal tacrolimus therapy was ≥1.0 μg/mL in 87% and >2.0 μg/mL in 56.5%. Conclusion: MPA TDM-based MMF dosage adjustment enabled us to administer MMF more confidently than categorical dosing. MPA TDM appears to be a useful tool to cope with the wide pharmacokinetic variability of MMF after liver transplantation.

AB - Background: Recent findings have suggested the clinical utility of therapeutic drug monitoring (TDM) in patients treated with mycophenolate mofetil (MMF). Aim: To assess whether routine mycophenolic acid (MPA) TDM is beneficial and how to utilize it. Methods: A series of short-term prospective studies on TDM for MPA and/or tacrolimus was performed at a large-volume center. Results: The 673 adult liver transplants were divided into four groups based on immunosuppressive regimens as tacrolimus monotherapy (n = 369), tacrolimus-MMF therapy (n = 270), MMF-minimal tacrolimus therapy (n = 17), and MMF monotherapy (n = 17). There was a significant difference of tacrolimus concentration between the groups receiving tacrolimus monotherapy and tacrolimus-MMF therapy during the first two yr (at two yr: 8.4 ± 2.7 vs. 6.3 ± 2.6 ng/mL; p ≤ 0.002). MMF-minimal tacrolimus therapy and MMF monotherapy were applied after first three months and MPA levels ranged from 1.8 to 5.3 μg/mL. Correlation between MMF dosage and MPA concentration showed wide interindividual variations (n = 304, r2 = 0.271, p < 0.001), in which r2 was fluctuating from 0.056 to 0.213 according to the post-transplant period over five yr; wide intraindividual variation was also observed during the first two months (n = 12, r2 < 0.2, p > 0.195). About 10% of patients were classified as poor MMF absorber and excluded from MMF usage. Mean MPA level leading to successful MMF monotherapy or MMF-minimal tacrolimus therapy was ≥1.0 μg/mL in 87% and >2.0 μg/mL in 56.5%. Conclusion: MPA TDM-based MMF dosage adjustment enabled us to administer MMF more confidently than categorical dosing. MPA TDM appears to be a useful tool to cope with the wide pharmacokinetic variability of MMF after liver transplantation.

KW - Immunosuppression

KW - Liver transplantation

KW - Mycophenolate mofetil

KW - Mycophenolic acid

KW - Therapeutic drug monitoring

UR - http://www.scopus.com/inward/record.url?scp=77952940912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952940912&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0012.2009.01166.x

DO - 10.1111/j.1399-0012.2009.01166.x

M3 - Article

VL - 24

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 2

ER -